CG Oncology Shares Rise After Reporting Bladder Cancer Drug Durability in Phase 3 Trial

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

CG Oncology Shares Rise After Reporting Bladder Cancer Drug Durability in Phase 3 Trial

, MT Newswires - 12:36 PM ET 3/24/2025 default

12:36 PM EDT, 03/24/2025 (MT Newswires) -- CG Oncology ( CGON ) rose over 4% on Monday after the company said roughly 76% of patients in a phase 3 trial of cretostimogene for high-risk bladder cancer showed a complete response at some point.

As of Jan. 20, 46% of patients remained in complete response at 12 months, with 30 confirmed responses at 24 months.

The study evaluated cretostimogene monotherapy for high-risk Bacillus Calmette Guerin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Data show that 83 out of 110 patients in the trial achieved complete response at some point.

Data also showed that cretostimogene levels peaked immediately after administration and lasted locally for 4 to 5 days. There was no systemic exposure reported.

These results were presented at the recent annual European Association of Urology Congress in Madrid, Spain.

Price: 28.26, Change: +1.21, Percent Change: +4.47

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.